Product Description: 3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7].
Formula: C12H14N4O3
Citations: bioRxiv. 2024 July 27./Cancers (Basel). 2022 Jul 23;14(15):3600./Cell Death Dis. 2020 Oct 23;11(10):906./Cell Death Discov. 2024 Jul 28;10(1):341./Cell Rep. 2023 May 23;42(6):112550./Cell Reprogram. 2017 Dec;19(6):363-371./Cells Tissues Organs. 2021 Jan 18;1-9./Genes. 2024 Sep 13./Int Immunopharmacol. 2022 Feb 19;106:108612./J Am Soc Nephrol. 2016 Jul;27(7):2021-34. /J Immunother Cancer. 2019 Nov 14;7(1):300. /J Mol Cell Cardiol. 2019 Oct;135:119-133./Lab Invest. 2021 Mar 10./Nat Commun. 2021 Feb 23;12(1):1237./Patent. US20180263995A1./Research Square Preprint. 2020 May./Research Square Print. September 13th, 2022./Apoptosis. 2020 Oct;25(9-10):697-714./Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067./bioRxiv. 2023 Apr 21./bioRxiv. 2024 May 18./Cell Signal. 2023 Dec 30:115:111029./Exp Mol Pathol. 2020 Feb;112:104344./J Pharmacol Exp Ther. 2019 Sep;370(3):490-503./Nat Commun. 2022 Jan 10;13(1):12./Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.
References: [1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743./[2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46./[3]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43./[4]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302./[5]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34./[6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146./[7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.
CAS Number: 102052-95-9
Molecular Weight: 262.26
Compound Purity: 99.97
Research Area: Cancer; Infection
Solubility: H2O : 100 mg/mL (ultrasonic)
Target: Histone Methyltransferase;Orthopoxvirus
English
Deutsch
